29/06/2022at 13:49

Overview: Pharma giants and Bavarian Nordic fight over billion-dollar vaccine market

There is currently no approved vaccine for RSV, which causes serious illness and can be deadly for newborns and the elderly. The race to come first to the vaccine market is heating up, while more companies are close to completing phase III studies. Get an overview of their progress here.

by christian bundgaard, translated by catherine brett

Respiratory Syncytical Virus, or RSV, causes a respiratory infection. It might not sound dangerous, but it can be.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Bavarian Nordic CEO shows no mercy to competitors as firm continues partner hunt: "If they fail, the value of our program increases"
For subscribers
GSK reports positive RSV vaccine data
For subscribers
EMA awards priority status to Bavarian Nordic's RSV vaccine for the over-60s
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Pharma & biotech

Adolescent patients' eczema improved in Leo Pharma's late-stage testing

Two phase III trials give the Danish dermatology company hope to see tralokinumab’s approved indication expanded to include the younger segment of teens.

For subscribers

Hearing health

DNB surprised by GN's lack of backup plan

For subscribers

Pharma & biotech

Leo Pharma presents positive data in hand eczema phase III trial

For subscribers

Foto: Guillaume Souvant/Reuters/Ritzau Scanpix

Pharma & biotech

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

For subscribers

Foto: Tingshu Wang/Reuters/Ritzau Scanpix

Regulation

Competition sharpens on active ingredient production – EU weighs measures

For subscribers

Pharma & biotech

Wegovy prescriptions in the US grow for another week

For subscribers

Sandoz finds multiresistant bacteria in six Dicillin batches as concerns grow

Sandoz confirms that bacteria have been found on the outside of capsules used in making the contaminated antibiotic product.

For subscribers

Foto: Athit Perawongmetha/Reuters/Ritzau Scanpix

Pharma & biotech

Pfizer’s RSV vaccine wins US panel’s backing for safety in older people

Though Pfizer’s vaccine against the lung disease gained support from the majority of the FDA’s panel, there were questions concerning the drug’s safety and data.

For subscribers

Foto: Lukas Barth/Reuters/Ritzau Scanpix

Pharma & biotech

Bavarian Nordic confident after FDA panel backs GSK, Pfizer RSV vaccines despite safety concerns

GSK and Pfizer admitted few cases of a rare autoimmune disease during clinical testing. ”We have really good experiences with our platform,” says Bavarian Nordic, reporting no such adverse reactions.

For subscribers